From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Rotigotine is a dopamine agonist used for Parkinson's disease and restless leg syndrome (RLS) which is available only as a slow-release transdermal patch applied to the skin.[1][2] Rotigotine is also sold under the brand name Neupro.[1][3] Rotigotine is in the same class of drugs as ropinirole and pramipexole.[4]

Theory[edit | edit source]

Evidence[edit | edit source]

No clinicial trials have yet been carried out of rotigotine for patients with ME/CFS.

A single study of rotigotine for fibromyalgia had high dropout rates for both the drug and placebo, but did not appear to show a significant improvement in pain or other fibromyalgia symptoms at doses of 4mg or 8mg.[4][5]

There is inconsistent evidence of the effect of rotigotine on fatigue in Parkinson's disease.[6][7]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

Notable studies[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]